Indivior's Biotech Stock Skyrockets 194% in a Year Despite Investor Exit

Stonepine Capital Management reduced its stake in Indivior PLC (NASDAQ:INDV) by 250,000 shares in Q3, decreasing the overall position value by $2.75 million. The fund now holds 100,000 shares worth $2.41 million, representing 1.96% of reportable AUM. Indivior shares are up 194% over the past year, vastly outperforming the S&P 500. The company's key products include SUBLOCADE, SUBUTEX PRO, SUBOXONE, OPVEE, and PERSERIS, targeting opioid use disorder and related conditions.